Live price temporarily unavailable.
Coya Therapeutics (COYA) is a Health Care company. Latest news and coverage below.
| FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $0 | $6.00M | $3.55M | $7.95M |
| Growth (year over year) | — | — | — | −40.8% | +123.6% |
| Operating income | −$4.87M | −$9.81M | −$7.90M | −$17.2M | −$22.6M |
| Operating margin | — | — | −131.7% | −485.4% | −283.9% |
| Net income | −$4.89M | −$12.2M | −$7.99M | −$14.9M | −$21.2M |
| Net margin | — | — | −133.1% | −418.7% | −267.1% |
| EPS (diluted) | −$1.89 | −$4.73 | −$0.79 | −$0.98 | −$1.27 |
| Balance sheet | |||||
| Cash and equivalents | $4.34M | $5.93M | $32.6M | $38.3M | $46.8M |
| Total assets | $4.79M | $8.40M | $41.3M | $44.3M | $50.0M |
| Total liabilities | $1.15M | $16.8M | $5.63M | $4.77M | $6.92M |
| Shareholders' equity | $3.64M | −$8.39M | $35.6M | $39.6M | $43.0M |
| Cash flow | |||||
| Operating cash flow | −$3.90M | −$7.24M | −$11.2M | −$10.3M | −$10.7M |
| Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $0 | — | $257.9K | $163.6K | $3.56M | — | $251.1K | $243.7K |
| Growth (year over year) | — | — | +103.3% | −95.2% | — | — | −2.6% | +49.0% |
| Operating income | −$4.45M | — | −$7.68M | −$6.41M | −$2.43M | — | −$7.64M | −$7.05M |
| Operating margin | — | — | −2976.9% | −3920.5% | −68.3% | — | −3042.1% | −2891.1% |
| Net income | −$4.02M | — | −$7.31M | −$6.09M | −$2.12M | — | −$7.21M | −$6.64M |
| Net margin | — | — | −2833.4% | −3725.2% | −59.4% | — | −2869.6% | −2723.4% |
| EPS (diluted) | −$0.26 | — | −$0.44 | −$0.36 | −$0.13 | — | −$0.32 | −$0.28 |
| Balance sheet | ||||||||
| Cash and equivalents | $31.1M | $38.3M | $35.5M | $29.8M | $28.1M | $46.8M | $50.7M | $43.2M |
| Total assets | $35.6M | $44.3M | $38.4M | $33.5M | $32.0M | $50.0M | $53.3M | $47.3M |
| Total liabilities | $3.54M | $4.77M | $5.04M | $5.14M | $4.76M | $6.92M | $4.30M | $4.03M |
| Shareholders' equity | $32.0M | $39.6M | $33.4M | $28.3M | $27.3M | $43.0M | $49.0M | $43.3M |
| Cash flow | ||||||||
| Operating cash flow | −$5.46M | — | −$2.83M | −$5.77M | −$1.13M | — | −$6.21M | −$7.38M |
From Coya Therapeutics's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Filings on SEC EDGAR →
No recent news mentioning Coya Therapeutics in our feed yet.